Mycoplasma hyopneumoniae avirulent adjuvanted live vaccine

A technology of mycoplasma hyopneumoniae and adjuvant, which is applied in the field of immunology and veterinary medicine, and can solve problems such as hindering the protection of immunogenicity of mycoplasma hyopneumoniae

Inactive Publication Date: 2010-11-10
ZOETIS W LLC
View PDF24 Cites 18 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Formalin inactivation significantly hampers protective immunogenicity of M. hyopneumoniae and this vaccine is ineffective

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Mycoplasma hyopneumoniae avirulent adjuvanted live vaccine
  • Mycoplasma hyopneumoniae avirulent adjuvanted live vaccine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0110] Example 1: Preparation of avirulent adjuvanted live vaccine of Mycoplasma hyopneumoniae

[0111] This example discloses the preparation of an exemplary adjuvanted avirulent live M. hyopneumoniae composition according to the present disclosure.

[0112] M. hyopneumoniae can be obtained from any readily available source. In one embodiment described herein, M. hyopneumoniae avirulent live culture strain J (FCX3-Line 1 ) was obtained from the American Type Culture Center (ATCC; Manassas, VA) as ATCC strain number 27715. Any other avirulent strain of M. hyopneumoniae may be used to prepare the composition, such as the parental J strain designated ATCC Accession No. 25934. In certain other embodiments, it is contemplated that any avirulent viable strain of M. hyopneumoniae can be adjusted, attenuated, or mutated until the culture is determined to be avirulent, as determined by in vitro or in vivo testing, using methods in the art Operations known to the skilled person. The...

Embodiment 2

[0118] Example 2: In vivo efficacy of avirulent adjuvanted live vaccine against Mycoplasma hyopneumoniae in pigs

[0119] This example demonstrates the in vivo efficacy of an exemplary adjuvanted avirulent live M. hyopneumoniae composition.

[0120] A total of 30 pigs, 4 to 6 weeks old, were obtained from Fort Dodge Animal Health's SPF herd located in Charles City, Iowa. Pigs were maintained without antibiotics or growth catalysts and were given water and food ad libitum. Animals receiving the vaccine and control compositions were housed in separate rooms and all pigs were maintained under similar conditions during vaccination, monitoring and challenge.

[0121] The 30 pigs were randomly assigned into three (3) groups as follows: one (1 ) group received the vaccine composition, one (1 ) group received placebo, and one (1 ) group served as an environmental control. Pigs were grouped as indicated in Table 2.

[0122] Table 2

[0123] Group

Total number of pigs# ...

Embodiment 3

[0150] Example 3: Preliminary immunogenicity study of the Mycoplasma hyopneumoniae part in the avirulent living strain of Mycoplasma hyopneumoniae-modified live porcine circovirus type 1-2 chimera

[0151] Combination vaccines in 3-4 week old pigs

[0152] This example discloses the efficacy of a combination vaccine comprising adjuvanted avirulent live M. hyopneumoniae J ( FCX3-line1) strain and porcine circovirus (PCV) type 1-type 2 chimera live vaccine (cPCV1-2; see US Patent Nos. 7,279,166 and 7,276,353). This combination vaccine (PCV / MH) is suitable for use in the vaccination of healthy pigs as an aid in preventing and / or reducing the severity of disease caused by M. hyopneumoniae and porcine circovirus.

[0153] Targeted test vaccines should contain approximately 4.0 Log 10 FAID 50 / dose of cPCV1 modified live virus and 4x10 8 CFU / dose of M. hyopneumoniae J strain (see King et al., Journal of Comparative Medicine and Vet. Science, 29:85-89 (1965) and US Pat. No. 4,...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Provided are immunogenic and vaccine compositions and methods for their preparation and use, which compositions are effective in protecting against, minimizing the severity of, preventing, and / or ameliorating M. hyopneumoniae infection. Administration to an animal of one or two doses of an adjuvanted live avirulent M. hyopneumoniae composition disclosed herein is effective in providing immunity to the animal and protection from infection with a virulent strain of M. hyopneumoniae thereby reducing the severity of and / or preventing disease caused by one or more virulent strain of M. hyopneumoniae. Also provided are compositions, which further comprise one or more antigen such as, for example, one or more live bacteria, bacterin, toxoid, and / or virus and / or viral antigen. Exemplified are immunogenic compositions, comprising an adjuvanted live avirulent M. hyopneumoniae and compositions, comprising Porcine Circovirus Type 1-Type 2 chimera modified live vaccine (cPCV1-2) in further combination with an adjuvanted live avirulent M. hyopneumoniae.

Description

field of invention [0001] The present disclosure relates generally to the fields of immunology and veterinary medicine. More specifically, the present disclosure provides adjuvanted avirulent live M. hyopneumoniae compositions, including immunogenic or vaccine compositions, based on the J strain of M. hyopneumoniae, which help reduce Severity of disease caused by one or more virulent strains of Mycoplasma and / or prevention of disease caused by one or more virulent strains of Mycoplasma hyopneumoniae. Also provided are adjuvanted avirulent live M. hyopneumoniae compositions, including immunogenic or vaccine compositions, further comprising porcine circovirus type 1-type 2 chimera modified live vaccines (cPCV1-2). Administration of one or two doses of an adjuvanted avirulent live M. hyopneumoniae composition disclosed herein to an animal is effective in providing immunity, including cell-mediated immunity, from infection by a virulent strain of M. hyopneumoniae and / or humoral ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/02C07K14/30
CPCA61K39/116A61K2039/522A61K39/0241A61K2039/55566C07K14/30A61K2039/70A61P31/00A61P31/04A61P37/00A61P37/04
Inventor H-J·楚Z·徐W·李N·R·吉布森
Owner ZOETIS W LLC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap